MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Search

Simulations Plus Inc

Cerrado

SectorSanidad

19.59 -2.29

Resumen

Variación precio

24h

Actual

Mínimo

19.4

Máximo

20.24

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

89.037

BPA

-0.034

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-8.83% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.18%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

42M

410M

Apertura anterior

21.88

Cierre anterior

19.59

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

30 / 352 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 ene 2026, 23:07 UTC

Ganancias

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 ene 2026, 21:27 UTC

Ganancias

Texas Instruments 4Q Sales Rise, Profit Falls

27 ene 2026, 23:55 UTC

Charlas de Mercado

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 ene 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 ene 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 ene 2026, 23:39 UTC

Charlas de Mercado

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 ene 2026, 23:20 UTC

Ganancias

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 ene 2026, 23:20 UTC

Ganancias

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 ene 2026, 23:19 UTC

Ganancias

SK Innovation Posts Net Loss for Second Consecutive Year

27 ene 2026, 23:19 UTC

Ganancias

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 ene 2026, 23:18 UTC

Ganancias

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 ene 2026, 23:18 UTC

Ganancias

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 ene 2026, 23:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 ene 2026, 23:11 UTC

Charlas de Mercado

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 ene 2026, 23:07 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 ene 2026, 22:17 UTC

Charlas de Mercado

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 ene 2026, 22:06 UTC

Ganancias

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 ene 2026, 21:51 UTC

Ganancias

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

27 ene 2026, 21:43 UTC

Ganancias

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 ene 2026, 21:41 UTC

Ganancias

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 ene 2026, 21:38 UTC

Ganancias

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 ene 2026, 21:32 UTC

Ganancias

Ampol: Modest Profit From F&I International in 2025

27 ene 2026, 21:32 UTC

Ganancias

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 ene 2026, 21:31 UTC

Ganancias

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 ene 2026, 21:31 UTC

Ganancias

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 ene 2026, 21:30 UTC

Ganancias

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 ene 2026, 21:29 UTC

Ganancias

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 ene 2026, 21:29 UTC

Ganancias

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 ene 2026, 21:28 UTC

Ganancias

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

-8.83% descenso

Estimación a 12 Meses

Media 19 USD  -8.83%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

2

Comprar

3

Mantener

0

Vender

Sentimiento

By Acuity

30 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat